Beta-lactam antibiotics use in intensive care units –  The pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach

Aneta Peric; Maja Šurbatović; Sandra Vezmar Kovačević; Mirjana Antunović; Milić Veljović; Ivana Krstić-Lečić; Dragan Djordjević; Vesna Kilibarda; Snježana Zeba; Silva Dobrić

doi:10.2298/5152

Aneta Peric Sector for Pharmacy, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Maja Šurbatović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia
Sandra Vezmar Kovačević Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Mirjana Antunović Sector for Pharmacy,Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Milić Veljović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia;Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia
Ivana Krstić-Lečić Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia
Dragan Djordjević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia;Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia
Vesna Kilibarda Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; National Poison Control Center, Military Medical Academy, Belgrade, Serbia
Snježana Zeba Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia;Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy, Belgrade, Serbia
Silva Dobrić Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Scientific Information, Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/5152

Keywords: lactams, pharmacoeconomics, pharmacokinetics, intensive care units, sepsis,

Abstract

References

Sharma S, Kumar A. Antimicrobial management of sepsis and septic shock. Clin Chest Med 2008; 29(4): 677−87.

Surbatovic M, Jevdjic J, Veljovic M, Popovic N, Djordjevic D, Radakovic S. Immune Response in Severe Infection: Could Life-Saving Drugs Be Potentially Harmful. Sci World J 2013; 2013: 961852.

Djordjević D, Surbatović M, Ugrinović D, Radaković S, Jevdjić J, Filipović N, et al. New aspects of sepsis pathophysiology in critically ill. Vojnosanit Pregl 2012; 69(1): 58−68.

Cavaillon J, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006; 12(3): 151−70.

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136(5): 123748.

Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348(16): 1546−54.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303−10.

Vincent J, Sakr Y, Sprung CL, Ranieri MV, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34(2): 344−53.

Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 2007; 35(11): 2538−46.

Delinger PR, Levy MM, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013; 41(2): 580−620.

Peric A, Vojvodic D, Baletic N, Peric A, Miljanovic O. Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154(4): 327−33.

Peric A, Peric AR, Vojvodic D. Anti-inflammatory effects of long-term low-dose clarithromycin administration in patients with nasal polyposis. Eur J Hosp Pharm 2012; 19(2): 197−8.

John JL, Devi P, John J, Guido S. Drug utilisation study of anti-microbial agents in medical intensive care unit of a tertiary care hospital. Asian J Pharm Clin Res 2011; 4(2): 81−4.

Craig WA. Choosing an antibiotic on the basis of pharmaco-dynamics. Ear Nose Throat J 1998; 77(Suppl 6): 7−11; discus-sion 11-2.

McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011; 66(Suppl. 2): 25−31.

Gould IM. Antibiotic policies and control of resistance. Curr Opin Infect Dis 2002; 15(4): 395−400.

Niwa T, Shinoda Y, Suzuki A, Ohmori T, Yasuda M, Ohta H, et al. Outcome measurement of extensive implementation of an-timicrobial stewardship in patients receiving intravenous anti-biotics in a Japanese university hospital. Int J Clin Pract 2012; 66(10): 999−1008.

Niederman MS. Appropriate use of antimicrobial agents: chal-lenges and strategies for improvement. Crit Care Med 2003; 31(2): 608−16.

Nicolau D. Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care 2008; 12(Suppl 4): S2.

Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm 2009; 15(2 Suppl): S18−23.

Brink AJ, Grolman F, Muckart D, Pretorius J, Richards GA, Senekal M, et al. Position statement: appropriate use of the carbape-nems. SAMJ 2004; 94(10): 855−62.

Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44(5): 539−49.

Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care 2008;12(Suppl 4): S3.

Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007; 67(7): 1027−52.

Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing an-timicrobial pharmacodynamics: dosage strategies for merope-nem. Clin Ther 2004; 26(8): 1187−98.

Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a re-view of its use in the treatment of serious bacterial infections. Drugs 2008; 68(6): 803−38.

Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44(10): 1009−34.

Boucher BA, Wood CG, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22(2): 255−71.

Surbatovic M, Radakovic S. Tumor necrosis factor-α levels early in severe acute pancreatitis: is there predictive value regarding severity and outcome. J Clin Gastroenterol 2013; 47(7): 637−43.

Surbatovic M, Veljovic M, Jevdjic J, Popovic N, Djordjevic D, Radakovic S. Immunoinflammatory Response in Critically Ill Patients: Severe Sepsis and/or Trauma. Mediators Inflamm 2013; 2013: 362793.

Surbatovic M, Grujic K, Cikota BM, Jevtic M, Filipovic N, Romic P, et al.. Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and in-terleukin-1ra in critically ill patients. J Crit Care 2010; 25(3): 542.

Gómez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43(7): 1798−802.

Taccone FS, Laterre P, Dugernier T, Spapen H, Delattre I, Witebolle X, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14(4): 126.

Georges B, Conil J, Seguin T, Ruiz S, Minville V, Cougot P, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother 2009; 53(10): 4483−9.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermit-tent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35(2): 156−63.

Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Aug-mented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49(1): 1−16.

Udy AA, Roberts JA, Lipman J. Augmented renal clearance: un-raveling the mystery of elevated antibiotic clearance. In: Vincent JL, editor. Yearbook of intensive care and emergency med-icine. Springer 2010. p. 495−506.

Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetics Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care 2012; 2(1): 35.

Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. In-tensive Care Med 2004; 30(12): 2145−56.

oberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus con-tinuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64(1): 142−50.

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Pipe-racillin penetration into tissue of critically ill patients with sep-sis: bolus versus continuous administration. Crit Care Med 2009; 37(3): 926−33.

DeRyke C, Young Lee S, Kuti JL, Nicolau DP. Optimizing dosing strategies of antibacterials utilising pharmacodynamic prin-ciples. Impact on the development of resistance. Drugs 2006; 66(1): 1−14.

Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Ni-colau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011; 37(4): 632−8.

Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22(4): 471−83.

Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimi-crob Chemother 1999; 43(4): 523−7.

Nicolau DP. Optimising antimicrobial therapy and emerging pathogens. Am J Manag Care 1998; 4(Suppl 2): 525−30.

van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intraven-ous antibiotic therapy. Crit Care 2003; 7(6): 184−90.

Perrott J, Mabasa VH, Ensom MH. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother 2010; 44(3): 557−64.

Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharma-codynamics of continuous versus short-term infusion of im-ipenem-cilastatin in critically ill patients in a randomized, con-trolled trial. Antimicrob Agents Chemother 2007; 51(9): 3304−10.

Kuti JL, Nightingale CH, Knauft FR, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004; 26(4): 493−501.

Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour in-fusion or bolus injection. Antimicrob Agents Chemother 2005; 49(4): 1337−9. PubMed PMID: 15793108

Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44(3): 357−63.

Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49(1): 461−3.

Eguchi K, Kanazawa K, Shimizudani T, Kanemitsu K, Kaku M. Ex-perimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmaco-dynamic model and Monte Carle stimulation. J Infect Che-mother 2010; 16(1): 1−9.

Dow RJ, Rose WE, Fox BC, Thorpe JM, Fish JT. Retrospective Study of Prolonged Versus Intermittent Infusion Piperacillin-Tazobactam and Meropenem in Intensive Care Unit Patients at an Academic Medical Center. Infect Dis Clin Pract 2011; 18(6): 413−7.

Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic bene-fit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2003; 60(6): 565−8.

van Zanten AR. The jury is still out on continuous infusion of beta-lactam antibiotics in intensive care patients. Crit Care Med 2009; 37(6): 2137−8.

Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liqiud chromatography with ultraviolet detection for real-time therapeutic drug monitoring of mero-penem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856(1−2): 371−5.

Kipper K, Anier K, Leito I, Karjagin J, Oselin K, Herodes K. Rapid determination of meropenem in biological fluids by LC: com-parison of various methods for sample preparation and inves-tigation of meropenem stability. Chromatographia 2009; 70(9−10): 1423−7.

Legrand T, Chhun S, Rey E, Blanchet B, Zahar J, Lanternier F, et al. Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 875(2): 551−6.

Denooz R, Charlier C. Simultaneous determination of five β-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 864(1−2): 161−7.